Abstract
Objective: To assess the role of the anti-TIF1γ auto-antibody (aAb) IgG2 isotype as a biomarker of cancer in anti-TIF1γ aAb-positive adult dermatomyositis (DM).
Methods: International multicenter retrospective study with the following inclusion criteria: i) diagnosis of DM according to ENMC criteria, ii) presence of anti-TIF1γ IgG aAb determined using an in-house addressable laser bead immunoassay (ALBIA) from cryopreserved serums sampled at time of DM diagnosis, iii) available baseline characteristics and follow-up data until the occurrence of cancer and/or a minimum follow-up of 1 year for patients without known cancer at diagnosis.
Detection and quantification of anti-TIF1γ IgG2 aAb was done using the in-house ALBIA. In addition, a recent enzyme-linked immuno-sorbent assay (ELISA) commercial kit was used for anti-TIF1γ IgG aAb quantification.
Results: A total of 132 patients (mean age 55+/- 15 years) of whom 72 (54.5%) had an associated cancer were analyzed. The association between the presence of cancer and the presence of anti-TIF1γ IgG2 aAb was statistically significant (p=0.026), with an OR of 2.26 (95%CI:1.10-4.76). Patients with cancer displayed significantly higher anti-TIF1γ IgG2 aAb ALBIA values with a median value of 1.15 AU/ml (IQR:0.14-9.76) compared to 0.50 AU/ml (IQR:0.14-1.46) for patients without cancer (p=0.042). In addition, patients with cancer displayed significantly higher anti-TIF1γ IgG aAb ELISA values with a median value of 127.5 AU/ml (IQR:81.5-139.6) compared to 93.0 AU/ml (IQR:54.0-132.9) for patients without cancer (p=0.004).
Conclusion: These results suggest considering anti-TIF1γ IgG2 ALBIA and IgG ELISA values as biomarkers of cancer in anti-TIF1 γ aAb-positive adult DM.
Methods: International multicenter retrospective study with the following inclusion criteria: i) diagnosis of DM according to ENMC criteria, ii) presence of anti-TIF1γ IgG aAb determined using an in-house addressable laser bead immunoassay (ALBIA) from cryopreserved serums sampled at time of DM diagnosis, iii) available baseline characteristics and follow-up data until the occurrence of cancer and/or a minimum follow-up of 1 year for patients without known cancer at diagnosis.
Detection and quantification of anti-TIF1γ IgG2 aAb was done using the in-house ALBIA. In addition, a recent enzyme-linked immuno-sorbent assay (ELISA) commercial kit was used for anti-TIF1γ IgG aAb quantification.
Results: A total of 132 patients (mean age 55+/- 15 years) of whom 72 (54.5%) had an associated cancer were analyzed. The association between the presence of cancer and the presence of anti-TIF1γ IgG2 aAb was statistically significant (p=0.026), with an OR of 2.26 (95%CI:1.10-4.76). Patients with cancer displayed significantly higher anti-TIF1γ IgG2 aAb ALBIA values with a median value of 1.15 AU/ml (IQR:0.14-9.76) compared to 0.50 AU/ml (IQR:0.14-1.46) for patients without cancer (p=0.042). In addition, patients with cancer displayed significantly higher anti-TIF1γ IgG aAb ELISA values with a median value of 127.5 AU/ml (IQR:81.5-139.6) compared to 93.0 AU/ml (IQR:54.0-132.9) for patients without cancer (p=0.004).
Conclusion: These results suggest considering anti-TIF1γ IgG2 ALBIA and IgG ELISA values as biomarkers of cancer in anti-TIF1 γ aAb-positive adult DM.
| Original language | English |
|---|---|
| Journal | Rheumatology (Print) |
| Publication status | Accepted/In press - 26 Sep 2022 |
